

1 Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D

2 Kim A. Gaffney¹, Adam Lucero¹, Lee Stoner², James Faulkner³, Patricia Whitfield^{4,5}, Jeremy
3 Krebs^{4,5}, David S. Rowlands¹.

4 ¹School of Sport and Exercise, Massey University Wellington, New Zealand.

5 ²Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, USA.

6 ³Department of Sport and Exercise, University of Winchester, Winchester, UK.

7 ⁴Centre for Endocrine, Diabetes and Obesity Research, Wellington Regional Hospital,
8 Wellington, New Zealand.

9 ⁵Department of Medicine, University of Otago, Wellington, Wellington, New Zealand.

10

11 Correspondence:

12 David S. Rowlands

13 School of Sport and Exercise

14 Massey University Wellington

15 63 Wallace St, Wellington, New Zealand

16 Tel: +64 4 801 5799

17 D.S.Rowlands@massey.ac.nz

18

19 Running title: Whey and exercise on glycaemic control in T2D

20 Clinical Trial Registration: ACTRN12613000340730.

21 Funding: School of Sport and Exercise Post-Graduate student project grant

22 Conflict of Interest: No author conflict of interest declared.

23

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam; Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science in Sports & Exercise*: Post Acceptance: 14 August 2017.
<https://doi.org/10.1249/MSS.0000000000001404>

24 **Abstract**

25 While intense endurance and resistance exercise training and whey protein supplementation
26 have both been shown to independently improve glycaemic control, no known studies have
27 examined the effect of high-intensity mixed-mode interval training (MMIT) and whey
28 supplementation in adults with Type-2 diabetes (T2D).

29 Purpose: To determine if peri-training whey protein supplementation combined with MMIT
30 can improve glycaemic control.

31 Methods: In a double-blind randomised controlled trial, 24 men (55.7 ± 5.6 y) with T2D
32 performed MMIT with whey (20 grams) or placebo control for 10 weeks. Glycaemic control
33 was assessed via glucose disposal rate (GDR) during a euglycaemic insulin clamp, fasting
34 blood glucose concentration (FBG), and HOMA-IR. Changes in peak oxygen consumption
35 (VO_{2peak}), 1-repetition maximum strength (1RM), Vastus lateralis (VL) muscle and
36 subcutaneous adipose thicknesses (SAT), and waist circumference (WC) were also assessed.

37 Results: 10-weeks of MMIT substantially improved GDR by 27.5% (90% CI 1.2%, 60.7%)
38 and 24.8% (-5.4%, 64.8%) in the whey and control groups, respectively. There were likely
39 and possible reductions in FBG by -17.4% (-30.6%, -1.6) and HOMA-IR by -14.1% (-25.3%,
40 1.08%) in the whey group, however, whey effects were not clearly beneficial to glycaemic
41 outcomes, relative to control. MMIT also clearly substantially improved 1RM by 20.6%
42 (16.3%, 24.9%) and 22.7% (18.4%, 27.2%), VO_{2peak} by 22.6% (12.0%, 26.2%) and 18.5%
43 (10.5%, 27.4%), VL muscle thickness by 18.9% (12.0%, 26.2%) and 18.6% (10.5%, 27.4%)
44 and possibly reduced WC by -2.1% (-3.1%, -1.0%) and -1.9% (-3.7%, -0.1%) in the control
45 and whey groups respectively, but the whey-control outcome was trivial or unclear.

46 Conclusion: A clinically-meaningful enhancement in glycaemic control following 10-
47 weeks of MMIT was not clearly advanced with peri-training whey protein supplementation in
48 middle-aged men with Type-2 diabetes.

49 Key Words: Milk-protein, exercise, diabetes, interval training, high-intensity, glucose
50 disposal.

51 **Introduction**

52 A central pathology of type-2 diabetes (T2D) is impaired glycaemic control, a
53 condition characterised by a diminished capacity to restore postprandial blood glucose
54 concentrations to homeostatic levels. Skeletal muscle is the major tissue of postprandial
55 glucose disposal (1), and a well-established site of dysfunction in T2D (2). It is well-
56 documented that T2D skeletal muscle displays low expression of proteins contributing to
57 glucose uptake and metabolism, including: contractile, glucose transporter, and mitochondrial
58 proteins (3-5). Exercise has been shown to upregulate the expression of these proteins (6, 7),
59 and it is well-established that the improvements in aerobic capacity, lean mass and strength
60 that follow progressive aerobic or circuit resistance training are also associated with better
61 glycaemic control (8, 9). High-intensity interval training has emerged as an effective low-
62 volume and time-efficient exercise mode for rapidly improving glycaemic control. In middle-
63 aged men with T2D, 2 weeks of high-intensity cycle interval training was shown to
64 significantly increase the expression of glucose transporter 4 (GLUT4) and mitochondrial
65 proteins in the *vastus lateralis* muscle and lower 24-hour blood glucose concentrations (6).

66 Milk protein supplementation has shown promise as a complementary therapeutic
67 agent to exercise for improving glycaemic control. Milk proteins are rich in amino acids that
68 stimulate protein synthesis in skeletal muscle (10), which may, like exercise training, lead to

69 better glycaemic control. Independently, whey supplementation was shown to improve
70 glucose tolerance and FBG after 8 weeks in insulin resistant rats (11, 12) and HOMA-IR after
71 12 weeks in overweight and obese adults (13). As an adjunct therapy to exercise and
72 compared to carbohydrate consumption alone, milk-protein supplementation for 6 weeks was
73 reported to improve VO_{2max} in treadmill trained sedentary men (14) and lean mass and 1RM
74 bench press strength after 8 weeks in mixed-mode trained female college basketball players
75 (15). As each of those outcomes has been previously associated with improved glycaemic
76 control (9, 16, 17) combined treatments may also provide better therapeutic outcomes than
77 exercise alone in populations with T2D.

78 The aim of this study was to determine whether whey supplementation for 10 weeks
79 would improve glycaemic control in a population with T2D performing high-intensity mixed-
80 mode interval training. We hypothesised that whey supplementation would enhance
81 glycaemic control to a greater extent than exercise alone. If effective, this may provide a
82 practical adjunct therapy to exercise for improving T2D rehabilitation outcomes.

83

84 **Methods**

85 *Participants*

86 Men with T2D ($n=24$) were recruited from local medical centres in Wellington, NZ.
87 Inclusion characteristics were age 40-65 y, BMI<40, not requiring insulin therapy, and not
88 meeting the ACSM guidelines for exercise for T2D (18). Ethics was approved by the
89 Northern B Health and Disability Ethics Committee, Ministry of Health, Wellington NZ
90 (13/NTB/69). Participants provided written informed consent.

91

92 *Experimental Design*

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam; Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science in Sports & Exercise*: Post Acceptance: 14 August 2017.
<https://doi.org/10.1249/MSS.0000000000001404>

93 The design was a double blind, randomized (Research Randomizer, Version 4.0,
94 <http://www.randomizer.org>), placebo controlled trial (<http://www.anzctr.org.au/>, Registration
95 number ACTRN12613000340730). At early stages of data collection, the original intended
96 third group: whey without MMIT, was removed from the study design because recruited
97 eligible participants declined to participate if not randomised to an exercise group creating
98 sampling bias. In the two-group design, participants consumed a whey-protein beverage or
99 carbohydrate placebo before and after 45 early-morning MMIT sessions over 10 weeks.
100 Participants were encouraged to maintain dietary and medication habits throughout the
101 experimental period and not to participate in strenuous activity within 2 days of testing
102 sessions. Participants were familiarised with all testing procedures except the euglycaemic
103 insulin clamp prior to baseline testing. Cardiac screening via ECG was performed at
104 familiarisation during a VO_{2peak} cycling test. Baseline testing occurred 5-10 days prior to
105 commencement of the intervention with post-testing 2 days after 45 exercise sessions. The
106 post glucose clamp was performed 48 hours after maximal cycling and strength tests to
107 provide a washout period that would allow for the bulk of the acute effects of intense exercise
108 on glycaemia to return to pre-exercise levels without inducing a period of deconditioning (19,
109 20).

110

111 *Exercise Protocol*

112 Participants completed 27 cycling and 18 resistance training sessions (4-5 sessions each
113 week). Sessions included a 5-minute warm-up at low intensity on a cycle ergometer or
114 rowing machine followed by 20 minutes of 1-minute interval style cycling or resistance
115 exercise. Pre-programmed cycling sessions (VeloTron Racer Mate, Seattle, WA) included 10

116 intervals at 70%-90% (increased 5% every 2 weeks) of the participants' peak oxygen
117 consumption volume (VO_{2peak}) obtained from baseline and fortnightly cycle testing
118 (SensorMedics Vmax, YorbaLinda, CA), with 1-minute active recovery intervals at 40% of
119 peak workload. Resistance training included 5 sets of 30 repetitions of each exercise (Day 1:
120 bench press and seated rows), and (Day 2: lateral pulldowns and barbell upright rows) with 1
121 minute of crunches on a fitball (Hart Sport, Auckland, NZ) as active recovery. Intensity was
122 set at 20% of 1-repetition maximum (1RM) during weeks 1-2 and increased to 25% of 1RM
123 to elicit a high-intensity workload, for the remainder of the intervention based upon baseline
124 and fortnightly testing. If participants were unable to maintain a set cycling or strength
125 workload for a full minute the subsequent interval was reduced by 10%. All exercise and
126 testing sessions were supervised by the researchers.

127

128 *Supplement*

129 Participants appeared each morning to the exercise laboratory in a fasted state. A chocolate
130 flavoured whey protein isolate (WPI-895, Fonterra, Auckland, New Zealand) beverage (20
131 grams protein/10 grams carbohydrate/3 grams milk-fat) or an identically-flavoured but non-
132 protein formulated isocaloric beverage (30 grams carbohydrate/3 grams milk-fat) was
133 consumed immediately before and after each exercise session. Each drink contained 175
134 calories (731 kilojoules). To reduce hunger and provide opportunity for a clear peri-training
135 whey compared to carbohydrate consumption effect to be observed, each participant
136 consumed a low-protein snack bar (Nature Valley, General Mills, Auckland, NZ) 1 hour after
137 exercise and resumed normal eating habits after 2 hours.

138

139 *Glycaemic Measures*

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam;
Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey
Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science
in Sports & Exercise*: Post Acceptance: 14 August 2017.
<https://doi.org/10.1249/MSS.0000000000001404>

140 Glucose disposal rate (GDR) for each individual was determined via a modified euglycaemic
141 insulin clamp as described previously (21). Briefly, participants appeared for testing between
142 7 and 9 am after an overnight fast and at least 48 hours after the last exercise testing session.
143 A catheter was placed at the antecubital vein for insulin and glucose infusion, and dorsally at
144 the hand for blood draws. Arterialised blood was obtained by placing the hand in a heater box
145 at 50 °C. Participants received priming insulin doses of 160 mU·m²·min⁻¹ for 4 minutes and
146 80 mU·m²·min⁻¹ for 3 minutes, after which the dosage was reduced to 40 mU·m²·min⁻¹ for
147 the remainder of the clamp. A 25% glucose infusion was initiated at 15 minutes or sooner if
148 fasting blood glucose levels were below 6.5 mmol·L⁻¹ and adjusted after 5-minute blood
149 glucose readings until stabilised at 5 mmol·L⁻¹. As this method elevated blood insulin
150 concentrations within a physiological rather than a supraphysiological range, the time to
151 stabilisation was variable between participants. GDR was calculated from the average rate of
152 glucose infused (mg·kg⁻¹·min⁻¹) during a 60 minute stabilisation phase. Fasting blood
153 samples were obtained to determine FBG and HOMA-IR.

154

155 *Physical Exercise Capacity*

156 Participants completed a continuous ramp protocol to volitional exhaustion on a cycle
157 ergometer commencing at 40 Watts for 3 minutes and increasing 1 Watt every 4 seconds.
158 Participants were encouraged to maintain a cadence of 70 rpm during the ramp. Peak oxygen
159 consumption (mL·kg⁻¹·min⁻¹) was measured as the average of the highest 30-second
160 consumption rate during the test. Acceptance of a maximal effort was dependent upon the
161 participant achieving a maximal Borg Scale (1-20) rating and/or an RER>1.15. Estimated 1
162 repetition-maximum (1RM) tests were completed at baseline and every 2 weeks for smith

163 machine bench press, lateral pulldown, seated row and barbell upright row during a maximal-
164 effort of 3-6 repetitions and predicted via the Brzycki Formula (22).

165

166 *Body Composition*

167 Body composition measures were taken in a fasted state prior to exercise testing. VL
168 thickness and subcutaneous adipose tissue (SAT) were measured after lying supine for 15
169 minutes via B-mode ultrasound (Terason T32000, Teratech Corp., Burlington, MA) using
170 previously validated protocols (23, 24) modified to include measurement of SAT at the
171 biceps and cross-section diameter at the VL muscle. Measurements were taken in a supine
172 position after participants had been lying relaxed for 15 minutes and then analysed using
173 ImageJ software (National Institute of Health, Bethesda, Maryland). SAT was determined
174 from the sum of adipose thickness at 4 standard calliper sites: thigh, calf, biceps, and triceps
175 and VL thickness from the maximal cross-sectional diameter measured at 1/3 the distance
176 from the centre of the patella to the tubercle of the anterior superior iliac spine.

177

178 *Statistical Methods*

179 Sample size estimation was based upon the primary outcome GDR using the test-
180 retest values reported by Defronzo et al (25) in a healthy adult population and upon sample
181 size estimations for magnitude based clinical inference (26, 27). The typical error of
182 measurement was doubled to allow for uncertainty in variability in a T2D population
183 and n was increased by 10% to allow for potential dropouts, which brought the required
184 sample to 24. The threshold for smallest worthwhile clinical change in GDR was 5.4% based
185 upon the effect of 3 months of hypoglycaemic therapy (Metformin) on naïve Type-2 diabetics
186 (28).

187 The effect of treatment and time on all dependent variables was estimated from mixed
188 models (Proc Mixed, SAS Version 9.1; SAS Institute, Cary, NC). Data were log transformed
189 prior to analysis. Total 1RM strength was expressed as the back log-transformed average of 4
190 log-transformed lift scores. Uncertainty was presented as 90% confidence limits or *P* value.
191 Magnitude-based inference was employed to infer clinical and mechanistic outcome effects
192 (27, 29). The probability that a contrast was at least greater than the clinical threshold or
193 smallest Cohen's *d* standardized difference ($0.2 \times$ baseline SD) was: 25-75% possible, 75-
194 95% likely, 95-99.5% very likely, >99.5% almost certain (27). In the case where the majority
195 (>50%) of the CI lay between the thresholds for positive and negative substantiveness, the
196 effect was qualified trivial (negligible) with the respective probabilities as above (30). The
197 terms *benefit*, *trivial (negligible)*, and *harm* refer to the most likely directional outcome,
198 relative to the smallest effect threshold. The terms *unclear*, *inconclusive* refers to outcomes
199 where the likelihood of both benefit and harm exceeded 5%. The likelihood of a clinical
200 benefit of intervention was expressed as the benefit:harm odds ratio, with 66:1 the smallest
201 adoption threshold (27). Pre- and post-intervention scores are presented in figures as raw
202 means and standard deviations.

203

204 **Results**

205 Twenty-four men with T2D were recruited to the study (Figure 1). There were no
206 clear differences between group characteristics at baseline (Table 1). All participants
207 completed the 45 exercise sessions within the 10-week period. The glycaemic control
208 outcomes and statistical summary for all parameter measures are in Figure 2 and Table 2,
209 respectively. Ten weeks of MMIT produced a clinically meaningful enhancement in GDR in

210 the whey and control groups, respectively, relative to the smallest threshold change (5.4%);
211 however, the whey-control difference was unclear. The secondary outcome measures of
212 glycaemic control (FBG and HOMA-IR) showed a likely and possible benefit of whey
213 supplementation on FBG, and possible and unclear benefits on HOMA-IR in the whey and
214 control groups respectively, reaching the adoption threshold (OR>66:1) only in the Whey
215 group; however, there was also no clear difference in the Whey-Control contrast. Very likely
216 and almost certain improvements in VO_{2peak} , 1RM strength and VL muscle thickness in
217 response to 10-weeks of MMIT in both the Whey and Control groups were observed (Figure
218 3), but the whey-control differences were also negligible and unclear. There was a possible
219 decrease in WC in both groups and a possible decrease in SAT in the whey group only (Table
220 2).

221

222 **Discussion**

223 The current study showed that consumption of 20 grams of whey protein before and
224 after MMIT for 10 weeks did not enhance glycaemic control in a T2D population assessed
225 via measures of glucose disposal rate, fasting blood glucose, and HOMA-IR. Similarly, whey
226 supplementation did not enhance any of the exercise performance adaptations accruing in
227 response to MMIT, including VO_{2peak} , 1RM strength, and muscle thickness. While previous
228 evidence indicates that whey supplementation and high-intensity interval training
229 independently improve glycaemic control (6, 13), no clear benefit of combined therapies was
230 observed.

231 Previously, consumption of 10 grams of whey protein hydrolysate before and after
232 resistance training for 10 weeks was shown to significantly increase quadriceps cross-

233 sectional area in healthy trained men (31). In addition, consumption of a single-dose of a
234 mixed milk-protein (20 grams) carbohydrate beverage after treadmill training for 6 weeks
235 significantly increased VO_{2max} in sedentary middle-aged men compared to an isocaloric
236 carbohydrate control (14). As both the increase in mid-thigh muscle cross-sectional area and
237 VO_{2peak} following exercise intervention have been previously associated with improved
238 HbA1c in populations with Type-2 diabetics (9, 17), we predicted that peri-training whey
239 supplementation for 10 weeks would lead to better glycaemic control than the MMIT alone.
240 Our observation that whey supplementation did not clearly increase muscle thickness at the
241 VL or VO_{2peak} suggests that adaptive responses previously seen in exercising healthy
242 populations may be lost with the development of T2D and may explain why we saw no effect
243 of whey protein on GDR, FBG or HOMA-IR.

244 It is possible that adults with T2D require a larger dose of milk-protein to induce
245 clinically meaningful outcomes. 20 grams of protein has been reported to be the optimal
246 dosage for improving protein synthetic responses in the skeletal muscle of healthy young men
247 (32). While we also provided a total of 40 g of protein as 20 g before and 20 g after MITT, in
248 another study in healthy elderly individuals (71 ± 4 y), 40 grams of whey protein increased
249 muscle protein synthesis after resistance training compared to a 20 gram dose (33). The
250 cohort in the current study was middle-aged (55.6 ± 5.7 y), however, T2D skeletal muscle has
251 been shown to display characteristics of aged tissue, including: accelerated muscle wasting
252 (34); lower contractile strength to muscle volume (35), and decreased mitochondrial density
253 (36). Future investigations should test dosage effects on muscle protein synthetic responses in
254 a population with T2D.

255 While we saw no clear benefits of whey supplementation on glycaemic control in this
256 study, there was some evidence that the protein exposure produced a more pronounced effect

257 on each of the glycaemic measures compared to exercise alone, as suggested through the
258 observation of a substantially larger clinically-beneficial odds ratios for GDR, FBG, and
259 HOMA-IR in the whey compared to the control group. We also observed that the adoption
260 threshold (odds ratio >66) was reached for FBG, HOMA-IR and SAT only in the whey
261 group, suggesting that the magnitude of the improvements in those secondary outcomes was
262 sufficient to justify treatment use only when therapies were combined. It is important to
263 acknowledge, however, that the full placebo-control adjusted outcome (whey-control), which
264 takes into account the on-study effect, left a statistically unclear whey-protein effect. We
265 suggest that a longer intervention or a larger cohort (to increase study power) may have
266 clarified whether whey supplementation was enhancing the pattern for improvement in
267 clinical outcomes.

268 An inherent potential confounder of investigations with control of energy intake was
269 that the control group was consuming substantially more carbohydrate each training morning
270 than the whey group (60 compared to 20 grams). We reasoned that while there was potential
271 for the control group to be consuming more carbohydrate than their normal dietary intake,
272 which could be deleterious to glycaemic control, we expected that the metabolic demands of
273 20 minutes of MMIT would obviate any effect on post-exercise blood glucose concentration
274 in a previously sedentary population. In addition, 6 x 20 minute sessions of high-intensity
275 interval cycling was previously shown to significantly improve postprandial and 24-hour
276 blood glucose regulation in middle-aged adults with T2D (6). Our findings confirm that
277 chronic intense interval training is effective for improving glycaemic control in populations
278 with T2D. We also found that the 5-days per week, mixed-mode training regime was well-
279 adhered to by a previously sedentary, middle-aged T2D population, improved glucose
280 disposal rates by a 4-5-fold greater magnitude than an equivalent duration of

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam; Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science in Sports & Exercise*: Post Acceptance: 14 August 2017.
<https://doi.org/10.1249/MSS.0000000000001404>

281 pharmacotherapy (Metformin) alone (28), and negated the potentially deleterious impact of
282 consuming 2 × 30 grams of a carbohydrate beverage each morning. Therefore, the MMIT
283 mode of exercise training may prove to be highly effective for improving T2D health
284 outcomes in long-term rehabilitation programs where high intensity exercise is appropriate.

285 In conclusion, consumption of 20 grams of whey protein before and after high-
286 intensity mixed-mode interval training for 10 weeks, compared to isocaloric non-protein
287 control, did not clearly enhance glycaemic control, VO_{2peak}, 1RM strength, or VL muscle
288 cross-section diameter in middle-aged men with T2D. These findings suggest that over short-
289 term interventions, populations with T2D may be resistant to nutritional stimulation of this
290 nature. However, recent dose response data, and patterns for greater gains in some clinical
291 parameters in the whey group support further investigation of the nutritional intervention,
292 possibly increasing the supplement dose or the intervention period.

293

294 **Acknowledgements**

295 Technical assistance: Richard Carroll, and Mark Henderwood. Research assistance:
296 Romain Boulay, Marine Perez, Alexandra Doittau, Cassandre Dujardin, and Julie Godoye.
297 Study Funding: School of Sport and Exercise project grant. The authors report no conflict of
298 interest. The results of the study are presented clearly, honestly, and without fabrication,
299 falsification, or inappropriate data manipulation. The results of the study do not constitute
300 endorsement by the American College of Sports Medicine.

301

302

303 **References**

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam; Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science in Sports & Exercise*: Post Acceptance: 14 August 2017.
<https://doi.org/10.1249/MSS.0000000000001404>

- 304 1. Thiebaud D, Jacot E, DeFronzo RA, Maeder E, Jequier E, Felber J. The Effect of
305 Graded Doses of Insulin on Total Glucose Uptake, Glucose Oxidation, and Glucose Storage
306 in Man. *Diabetes*. 1982; 31(11): 957-63.
- 307 2. Bjornholm M, Zierath JR. Insulin signal transduction in human skeletal muscle:
308 identifying the defects in Type II diabetes. *Biochem. Soc. Trans.* 2005; 33(Pt 2): 354-7.
- 309 3. Mullen E, Ohlendieck K. Proteomic profiling of non-obese type 2 diabetic skeletal
310 muscle. *Int. J. Mol. Med.* 2010; 25(3): 445-58.
- 311 4. Hwang H, Bowen BP, Lefort N, et al. Proteomics analysis of human skeletal muscle
312 reveals novel abnormalities in obesity and type 2 diabetes. *Diabetes*. 2010; 59(1): 33-42.
- 313 5. Kampmann U, Christensen B, Nielsen TS, et al. GLUT4 and UBC9 Protein
314 Expression Is Reduced in Muscle from Type 2 Diabetic Patients with Severe Insulin
315 Resistance. *PLoS One*. 2011; 6(11): e27854.
- 316 6. Little JP, Gillen JB, Percival ME, et al. Low-volume high-intensity interval training
317 reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2
318 diabetes. *J. Appl. Physiol.* 2011; 111(6): 1554-60.
- 319 7. Son HJ, Kim HJ, Kim CK. The Effect of Resistance and Endurance Exercise Training
320 on Muscle Proteome Expression in Human Skeletal Muscle. *Biol. Sport*. 2012; 29(2): 121-7.
- 321 8. Gillen JB, Martin BJ, MacInnis MJ, Skelly LE, Tarnopolsky MA, Gibala MJ. Twelve
322 Weeks of Sprint Interval Training Improves Indices of Cardiometabolic Health Similar to
323 Traditional Endurance Training despite a Five-Fold Lower Exercise Volume and Time
324 Commitment. *PLoS One*. 2016; 11(4): e0154075.
- 325 9. Kang S, Woo JH, Shin KO, et al. Circuit resistance exercise improves glycemic
326 control and adipokines in females with type 2 diabetes mellitus. *J. Sports Sci. Med.* 2009;
327 8(4): 682-8.

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam; Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science in Sports & Exercise*: Post Acceptance: 14 August 2017.
<https://doi.org/10.1249/MSS.0000000000001404>

- 328 10. Bohe J, Low A, Wolfe RR, Rennie MJ. Human muscle protein synthesis is modulated
329 by extracellular, not intramuscular amino acid availability: a dose-response study. *J Physiol*
330 (*Lond*). 2003; 552(1): 315-24.
- 331 11. Belobrajdic DP, McIntosh GH, Owens JA. A high-whey-protein diet reduces body
332 weight gain and alters insulin sensitivity relative to red meat in wistar rats. *J. Nutr.* 2004;
333 134(6): 1454-8.
- 334 12. Tong X, Li W, Xu JY, Han S, Qin LQ. Effects of whey protein and leucine
335 supplementation on insulin resistance in non-obese insulin-resistant model rats. *Nutrition*.
336 2014; 30(9): 1076-80.
- 337 13. Pal S, Ellis V, Dhaliwal S. Effects of whey protein isolate on body composition,
338 lipids, insulin and glucose in overweight and obese individuals. *Br. J. Nutr.* 2010; 104(5):
339 716-23.
- 340 14. Robinson MM, Turner SM, Hellerstein MK, Hamilton KL, Miller BF. Long-term
341 synthesis rates of skeletal muscle DNA and protein are higher during aerobic training in older
342 humans than in sedentary young subjects but are not altered by protein supplementation.
343 *FASEB Journal*. 2011; 25(9): 3240–49.
- 344 15. Taylor LW, Wilborn C, Roberts MD, White A, Dugan K. Eight weeks of pre- and
345 postexercise whey protein supplementation increases lean body mass and improves
346 performance in Division III collegiate female basketball players. *Appl. Physiol. Nutr. Metab.*
347 2016; 41(3): 249-54.
- 348 16. Bacchi E, Negri C, Zanolin ME, et al. Metabolic effects of aerobic training and
349 resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2
350 study). *Diabetes Care*. 2012; 35(4): 676-82.

- 351 17. Larose J, Sigal RJ, Khandwala F, Prud'homme D, Boule NG, Kenny GP. Associations
352 between physical fitness and HbA(1c) in type 2 diabetes mellitus. *Diabetologia*. 2011; 54(1):
353 93-102.
- 354 18. Colberg SR, Albright AL, Blissmer BJ, et al. Exercise and type 2 diabetes: American
355 College of Sports Medicine and the American Diabetes Association: joint position statement.
356 Exercise and type 2 diabetes. *Med. Sci. Sports Exerc.* 2010; 42(12): 2282-303.
- 357 19. Black LE, Swan PD, Alvar BA. Effects of intensity and volume on insulin sensitivity
358 during acute bouts of resistance training. *J. Strength Cond. Res.* 2010; 24(4): 1109-16.
- 359 20. Marliss EB, Vranic M. Intense exercise has unique effects on both insulin release and
360 its roles in glucoregulation: implications for diabetes. *Diabetes*. 2002; 51(2): 271-83.
- 361 21. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose
362 tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes*. 1999; 22(9):
363 1462-70.
- 364 22. Brzycki M, *A Practical Approach To Strength Training*. 1999: McGraw-Hill.
- 365 23. Toomey C, McCreesh K, Leahy S, Jakeman P. Technical considerations for accurate
366 measurement of subcutaneous adipose tissue thickness using B-mode ultrasound. *Ultrasound*.
367 2011; 19(2): 91-6.
- 368 24. Thomaes T, Thomis M, Onkelinx S, Coudyzer W, Cornelissen V, Vanhees L.
369 Reliability and validity of the ultrasound technique to measure the rectus femoris muscle
370 diameter in older CAD-patients. *BMC Med. Imaging*. 2012; 12: 7.
- 371 25. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for
372 quantifying insulin secretion and resistance. *Am. J. Physiol. Gastrointest. Liver Physiol*.
373 1979; 237(3): E214.

- 374 26. Hopkins W, Batterham A. Error Rates, Decisive Outcomes and Publication Bias with
375 Several Inferential Methods. *Sports Med.* 2016; 46(10): 1563-73.
- 376 27. Hopkins W, Marshall S, Batterham A, Hanin J. Progressive statistics for studies in
377 sports medicine and exercise science. *Med Sci Sports Exerc.* 2009; 41(1): 3-13.
- 378 28. Derosa G, Maffioli P, Salvadeo SA, et al. Direct comparison among oral
379 hypoglycemic agents and their association with insulin resistance evaluated by euglycemic
380 hyperinsulinemic clamp: the 60's study. *Metabolism.* 2009; 58(8): 1059-66.
- 381 29. Burton PR, Gurrin LC, Campbell MJ. Clinical significance not statistical significance:
382 a simple Bayesian alternative to p values. *J Epidemiol Commun H.* 1998; 52(5): 318-323.
- 383 30. Hopkins WG, Marshall SW, Batterham AM, Hanin J. Progressive statistics for studies
384 in sports medicine and exercise science. *Med. Sci. Sports Exerc.* 2009; 41(1): 3-13.
- 385 31. Farup J, Rahbek SK, Matzon A, et al. Whey protein hydrolysate augments tendon and
386 muscle hypertrophy independent of resistance exercise contraction mode. *Scand. J. Med. Sci.*
387 *Sports.* 2014; 24(5): 788-98.
- 388 32. Moore DR, Robinson MJ, Fry JL, et al. Ingested protein dose response of muscle and
389 albumin protein synthesis after resistance exercise in young men. *Am J Clin Nutr.* 2009;
390 89(1): 161-8.
- 391 33. Yang Y, Breen L, Burd NA, et al. Resistance exercise enhances myofibrillar protein
392 synthesis with graded intakes of whey protein in older men. *Br J Nutr.* 2012; 108(10): 1780-
393 8.
- 394 34. Lee JSW, Kwok T, Woo J, Auyeung TW, Leung J, Leung PC. Pathophysiology The
395 effect of diabetes mellitus on age-associated lean mass loss in 3153 older adults. *Diabetic*
396 *Medicine.* 2010; 27(12): 1366-71.

397 35. Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and
398 quality in older adults with type 2 diabetes: the health, aging, and body composition study.

399 *Diabetes*. 2006; 55(6): 1813-8.


400 36. Chomentowski P, Coen PM, Radiková Z, Goodpaster BH, Toledo FGS. Skeletal
401 muscle mitochondria in insulin resistance: differences in intermyofibrillar versus

402 subsarcolemmal subpopulations and relationship to metabolic flexibility. *J Clin Endocrinol*

403 *Metab*. 2011; 96(2): 494-503.


404

405




406

407 **Figure 1.** Recruitment flowchart.



409 **Figure 2.** Effect of 10 weeks of peri-training whey supplementation on: A) glucose disposal
410 rate; B) fasting blood glucose concentration; and, C) HOMA-IR. Data are raw means and SD
411 for the Pre (baseline) and Post testing time points.



413 **Figure 3.** Effect of 10 weeks of peri-training whey supplementation on: A) VO_{2peak} ; B) 1RM
 414 strength (the back log-transformed average of 4 log-transformed lift scores); and, C) *vastus*
 415 *lateralis* muscle thickness. Data are raw means and SD for the Pre (baseline) and Post testing
 416 time points.
 417

Table 1. Baseline characteristics of the Control and Whey groups.

Parameter	Control	Whey
	n=12	n=12
Age (y)	Mean SD 57.8 ± 5.2	Mean SD 53.5 ± 5.6
Height (cm)	174.6 ± 7.1	177.1 ± 8.7
Weight (kg)	91.9 ± 15.5	92.8 ± 11.0
BMI (kg·m ²)	30.1 ± 4.9	29.6 ± 2.7
VO_{2peak} (mL·kg ⁻¹ ·min ⁻¹)	26.9 ± 10.2	28.7 ± 4.9
FBG (mmol·L ⁻¹)	9.4 ± 2.9	10.2 ± 3.6
GDR (mg·kg ⁻¹ ·L ⁻¹)	2.11 ± 1.4	1.93 ± 0.8
Time to euglycaemia (min)	106.3 ± 67.2	106.7 ± 53.9

Data are presented as means and standard deviations.

418

Table 2. The effect of 10-weeks peri-training whey-protein supplementation on established clinical measures of glycaemic control, exercise performance, and body composition.

Contrast ^a	% Change	Upper CI	Lower CI	Likelihood (%) benefit/trivial/harm ^b	Qualitative ^b	Benefit odds ^b
Glucose Disposal Rate						
Control	24.8	64.8	-5.4	90.1/7.1/2.8	Benefit likely	318
Whey	27.5	60.7	1.2	95.6/3.5/0.9	Benefit very likely	2424
Whey-Control	2.2	44.8	-28.0	42.6/24.4/33.0	Unclear	2
Fasting Blood Glucose						
Control	-8.1	10.7	-23.7	50.4/45.8/3.8	Benefit possible	26
Whey	-17.4	-1.6	-30.6	88.8/11.0/0.2	Benefit likely	3291
Whey-Control	-10	15.3	-29.8	57.3/35.9/6.8	Unclear	19
HOMA-IR						
Control	-5.3	28.3	-30.1	23.7/68.8/7.6	Unclear	4
Whey	-14.1	1.08	-25.3	42.0/58.0/0.0	Benefit possible	3331

This is a non-final version of an article published in final form in Gaffney, Kim A.; Lucero, Adam; Stoner, Lee; Faulkner, James; Whitfield, Patricia; Krebs, Jeremy; Rowlands, David S. (2017) "Nil Whey Protein Effect on Glycaemic Control after Intense Mixed-Mode Training in T2D." *Medicine & Science in Sports & Exercise*: Post Acceptance: 14 August 2017.

<https://doi.org/10.1249/MSS.0000000000001404>

Whey-Control	9.2	25.4	-34.2	35.0/59.1/6.0	Unclear	8
VO_{2peak}						
Control	22.6	26.2	12.0	99.8/0.2/0.0	Benefit almost certain	5.05E+07
Whey	18.5	27.4	10.5	99.1/0.9/0.0	Benefit very likely	2.81E+06
Whey-Control	-3.3	9.07	-8.75	4.4/69.1/26.5	Trivial possible	0
1-Repetition Maximum Strength^c						
Control	20.6	24.9	16.3	100/0.0/0.0	Benefit almost certain	3.29E+31
Whey	22.7	27.2	18.4	100/0.0/0.0	Benefit almost certain	7.80E+35
Whey-Control	1.8	7.1	-3.2	0.1/99.8/0.0	Trivial almost certain	11
Muscle Thickness						
Control	18.9	26.2	12.0	100/0.0/0.0	Benefit almost certain	1.78E+09
Whey	18.6	27.4	10.5	99.89/0.02/0.0	Benefit almost certain	6.62E+07
Whey-Control	-0.2	9.1	-8.8	13.6/70.6/15.9	Unclear	1
Waist Circumference						
Control	-2.1	-1.0	-3.1	41.0/59.1/0.0	Benefit possible	7.44E+05
Whey	-1.9	-0.1	-3.7	28.6/71.4/0.0	Benefit possible	2888
Whey-Control	0.1	2.1	-1.8	0.3/99.5/0.2	Trivial very likely	2
Subcutaneous Adipose Tissue^d						
Control	-1	6.9	-8.3	6.7/90.8/2.5	Trivial likely	3
Whey	-6.9	3.5	-16.2	43.7/55.8/0.5	Benefit possible	151
Whey-Control	-6.0	6.7	-17.1	40.1/57.9/2.0	Benefit possible	32

^a Data for each contrast are post-pre. ^b The threshold for smallest clinical effect for glucose disposal rate was 5.4% (28); and for all other measures the smallest standardised difference (0.2xSD). The likelihood that a contrast was at least greater than the clinical threshold was: 25-75% possible, 75-95% likely, 95-99.5% very likely, >99.5% almost certain. Unclear refers to outcomes where the likelihood of both benefit and harm exceeded 5%. The clinical adoption threshold was expressed as a benefit: harm odds ratio >66:1. ^c Total 1-Repetition Maximum strength was expressed as the back log-transformed average of 4 log-transformed lift scores. ^d Subcutaneous Adipose Tissue was expressed as the sum of 4 sites.